Everything below concerns FSFI desire score. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
== Medical uses == Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. In addition, several clinical studies have demonstrated that dapagliflozin can slow the progression of kidney disease, lower the risk of kidney failure, and reduce the risk of death when used alongside standard treatments such as blood pressure medications. These benefits have been witnessed in patients with chronic kidney disease and/or heart disease, regardless of diabetes. Guidelines including the European Society of Cardiology for Heart Failure and American Heart Association consider SGLT2 inhibitors such as dapagliflozin as standard therapy for people with heart failure with reduced ejection fraction, (LVEF < 40%). This is supported by two large, randomized, controlled trials and a 2023 systematic review and meta-analysis. Evidence from multiple studies indicates that the addition of dapagliflozin and other sodium‑glucose cotransporter 2 (SGLT2) inhibitors to standard heart failure therapy can reduce the risk of worsening heart failure and hospitalisation for heart failure, regardless of the presence or absence of diabetes. A reduction in cardiovascular death is robust in heart failure with reduced ejection fraction (HFrEF), type 2 diabetes (T2DM), and chronic kidney disease (CKD), but less certain in heart failure with preserved ejection fraction (HFpEF) and acute myocardial infarction (MI).
It is unlikely that a person would overdose on nicotine through smoking alone. The US Food and Drug Administration (FDA) stated in 2013 that there are no significant safety concerns associated with the use of more than one form of over-the-counter (OTC) nicotine replacement therapy at the same time, or using OTC NRT at the same time as another nicotine-containing product, like cigarettes. The median lethal dose of nicotine in humans is unknown. Nevertheless, nicotine has a relatively high toxicity in comparison to many other alkaloids such as caffeine, which has an LD50 of 127 mg/kg when administered to mice. At sufficiently high doses, it is associated with nicotine poisoning, which, while common in children (in whom poisonous and lethal levels occur at lower doses per kilogram of body weight) rarely results in significant morbidity or death. The estimated lower dose limit for fatal outcomes is 500–1,000 mg of ingested nicotine for an adult (6.5–13 mg/kg). The initial symptoms of a nicotine overdose typically include nausea, vomiting, diarrhea, hypersalivation, abdominal pain, tachycardia (rapid heart rate), hypertension (high blood pressure), tachypnea (rapid breathing), headache, dizziness, pallor (pale skin), auditory or visual disturbances, and perspiration, followed shortly after by marked bradycardia (slow heart rate), bradypnea (slow breathing), and hypotension (low blood pressure). An increased respiratory rate (i.e., tachypnea) is one of the primary signs of nicotine poisoning.
== External links == Allergies - Americal Academy of Allergy Asthma and Immunology Allergy Blood Testing - Lab Tests Online Radioallergosorbent+Test at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Despite the likely increased volcanism from early plate tectonics, the Earth may have been a predominantly water world between 4.4 and 4.3 Gya. It is debated whether crust was exposed above this ocean. Immediately after the Moon-forming impact, Earth likely had little if any continental crust, a turbulent atmosphere, and a hydrosphere subject to intense ultraviolet light from a T Tauri stage Sun. It was also affected by cosmic radiation, and continued asteroid and comet impacts. The Late Heavy Bombardment hypothesis posits that a period of intense impact occurred at 4.1 to 3.8 Gya during the Hadean and early Archean eons. Originally it was thought that the Late Heavy Bombardment was a single cataclysmic impact event occurring at 3.9 Gya; this would have had the potential to sterilize Earth by volatilizing liquid oceans and blocking sunlight needed for photosynthesis, delaying the earliest possible emergence of life. More recent research questioned the intensity of the Late Heavy Bombardment and its potential for sterilisation. If it was not one giant impact but a period of raised impact rate, it would have had much less destructive power. The 3.9 Gya date arose from dating of Apollo mission sample returns collected mostly near the Imbrium Basin, biasing the age of recorded impacts. Impact modelling of the lunar surface reveals that rather than a cataclysmic event at 3.9 Gya, multiple small-scale, short-lived periods of bombardment likely occurred.
== Clinical significance == Deletions and mutations in this gene are associated with supravalvular aortic stenosis (SVAS) and the autosomal dominant cutis laxa. Other associated defects in elastin include Marfan syndrome, emphysema caused by α1-antitrypsin deficiency, atherosclerosis, Buschke–Ollendorff syndrome, Menkes syndrome, pseudoxanthoma elasticum, and Williams syndrome.
Sources: en.wikipedia.org
=== EC 7.3 Catalysing the translocation of inorganic anions === This subclass contains translocases that transfer inorganic cations anions. Subclasses are based on the reaction processes that provide the driving force for the translocation. At present only one subclass is represented: EC 7.3.2 Translocation of inorganic anions linked to the hydrolysis of a nucleoside triphosphate.
He visited Calabria Citeriore, Sibari, Corigliano, Rossano, Cirò and Strongoli. Charles met the Dean of Catanzaro on the borders of Calabria Ulterior, stopped in Crotone and in Cutro, and stayed four days in Catanzaro, before visiting Monteleone and then Palmi. From there, Charles embarked for Messina. From the earliest years the reforming action of King Charles, aided by Tuscan minister Bernardo Tanucci, was aimed at strengthening central power at the expense of baronial and clerical power. He also worked to alleviate the social and economic conditions of the poor, with at best modest results, due to the resistance of the local ruling classes, fighting to protect their privileges and particularistic interests. One particularly reformed field was economic and fiscal: in 1739 the Supreme Magistrate of Commerce was created, consisting of magistrates, technicians, merchants and bankers, with absolute jurisdiction over trade. In 1741 a Concordat was made with the Holy See, allowing ecclesiastical properties in the Kingdom of Naples to be taxed, while in the same period the Catasto onciario was commissioned, so called because it was measured in ounces (nominal currency equal to 6 ducats or 60 carlins), which was supposed to reorder the tax burden by lowering taxes on the poorest. However, nobles and clergymen enjoyed exemptions that protected their interests. In 1759, however, King Charles, as a result of diplomatic agreements and complicated family events, had to abdicate the throne of Naples to secure the crown of Spain after the death of his half-brother Ferdinand VI.
=== Australia === From 2023, Juniper was cited in multiple reports examining the regulation of telehealth-based weight-loss services in Australia. The Royal Australian College of General Practitioners (RACGP) and medical regulators raised concerns about prescribing models relying on asynchronous or questionnaire-based assessments for injectable weight-loss medications. The TGA assessed whether online advertising by Juniper (and its competitors) could indirectly promote prescription-only medicines in breach of federal law. Between 2022 and 2024 they requested the removal of thousands of unlawful advertisements. In response to updated guidance from the Medical Board of Australia (MBA) restricting "tick-and-flick" prescribing, Eucalyptus Health said that its platforms would comply with requirements for real-time clinical consultation and enhanced verification. In July 2023, the TGA opened an investigation into whether email communications sent by Juniper to people on its contact list about the availability of Ozempic constituted unlawful advertising. Through 2024, the TGA proposed the removal of GLP-1 medicines from pharmacy compounding exemptions due to concerns that telehealth prescribing models were inconsistent with exemptions intended for individual patient use. They warned that compounded GLP-1 products were not subject to the same safety, quality, or adverse-event reporting requirements as TGA-approved medicines. Juniper was one of the companies prescribing them.
== In popular culture == In Agatha Christie's 1937 mystery Cards on the Table, Hexobarbital is used in conjunction with Veronal to induce overdose. It is referred to by Hercule Poirot as both N-methyl-cyclo-hexenyl-methyl-malonyl urea and Evipan. It was also used in Graham Greene's The Heart of the Matter (1948) Evipan was prescribed for a main character in tablet form to use as a sleeping aid.
==== Redesign of September 2022 ==== On 10 September 2022, Miguel Rodríguez Mackay resigned as Minister of Foreign Affairs. After a month as minister, the main disagreement was notably with President Castillo over the recognition and reestablishment of diplomatic ties with the Sahrawi Arab Democratic Republic, which Castillo reestablished two days earlier, on 8 September 2022. President Castillo was forced to reshuffle his government as a result and opted to bring former minister César Landa back to the Ministry of Foreign Affairs on 13 September. On 24 September 2022, Castillo reshuffled two portfolios, in particular that of the Ministry of Transportation due to Congress's censure of Minister Geiner Alvarado.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.